Adam Steinmetz
Papers
1
Total Citations
37
H-Index
1
About
Adam Steinmetz is a leading figure in theranostic oncology, with a primary focus on developing and translating novel radionuclide therapies for high-risk prostate cancer. His most impactful work centers on the preoperative application of 177Lu-PSMA-I&T, a targeted radionuclide treatment, as demonstrated in his landmark single-arm Phase 1 trial. This pioneering study, which has garnered 37 citations, established the safety and feasibility of delivering neoadjuvant radioligand therapy before radical prostatectomy, offering a potential paradigm shift in managing aggressive, localized disease. By integrating molecular imaging and therapy, Steinmetz’s research bridges the gap between systemic treatment and surgical intervention, aiming to improve outcomes for patients with high-risk prostate cancer. His contributions are particularly notable for advancing the clinical pipeline of PSMA-targeted agents, moving them beyond metastatic settings into earlier disease stages. This work has positioned him as a key innovator in the field, with his findings informing subsequent trials and shaping the future of precision oncology.
Research Focus
Key Achievements
Top Papers
- 1